Blog

Quick Take: Awakn announces that it is qualified to begin trading on the OTCQB Venture Market under the the ticker “AWKNF” starting today. Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market (“OTCQB”) under the ticker symbol “AWKNF” today, Tuesday, August 12, 2021. The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade. Trading on the OTCQB will enhance the visibility and accessibility…

Quick Take: Novamind has announced the completion of its investment in the Synthesis Institute, a psychedelic retreat and practitioner program located in the Netherlands. Novamind Inc. (CSE: NM, OTC: NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company’s investment in the Synthesis Institute, a leader in psychedelic retreats and practitioner training programs located in the Netherlands (“Synthesis”). Novamind led Synthesis’ seed financing in 2019 with a strategic investment of €750,000 (the “Strategic Investment”). Pursuant to the terms of an agreement between Synthesis and Novamind,…

Quick Take: MYND Life Sciences is now eligible for Depository Trust Company services in relation to the Company’s listing on the OTC. MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is pleased to announce that it is now eligible for Depository Trust Company (“DTC”) services in relation to the Company’s listing on the OTC. Through the OTC listing, investors from the United States may more easily trade MYNDF stock, in addition to MYND’s listing on the CSE “MYND” in Canada. “We are excited to receive DTC eligibility, which not…

Quick Take: Revive provides an update on their psychedelic product development pipeline. One key component of their research pipeline is the research of the use of psilocybin to treat traumatic brain injury and stroke. Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psychedelics development and clinical programs with a focus on psilocybin. “We are advancing a robust psychedelics-based product pipeline that includes product development, preclinical and clinical studies that aim to unlock the…

Quick Take: MindMed has appointed Dr. Robert Dworkin, a professor with over 35 years of conducting clinical research on pain, to its scientific advisory board. MindMed (NASDAQ: MNMD) (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain. He is currently Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Professor in the Center for Health + Technology, at the University of Rochester School of Medicine and Dentistry. He holds additional roles as the Director of the Analgesic,…